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Abstract: Hepatocellular carcinoma (HCC) is a deadly disease and therapeutic efficacy in advanced
HCC is limited. Since progression of chronic liver disease to HCC involves a long latency period of a
few decades, a significant window of therapeutic opportunities exists for prevention of HCC and
improve patient prognosis. Nonetheless, there has been no clinical advancement in instituting HCC
chemopreventive strategies. Some of the major challenges are heterogenous genetic aberrations of
HCC, significant modulation of tumor microenvironment and incomplete understanding of HCC
tumorigenesis. To this end, animal models of HCC are valuable tools to evaluate biology of tumor
initiation and progression with specific insight into molecular and genetic mechanisms involved.
In this review, we describe various animal models of HCC that facilitate effective ways to study
therapeutic prevention strategies that have translational potential to be evaluated in a clinical context.
Keywords: hepatocellular carcinoma; prevention; animal models
1. Introduction
Liver cancer is the sixth most common cause of cancer worldwide and accounted for nearly
780,000 deaths or 8% of all cancer related deaths as of 2018 [1]. Globally, liver cancers are more common
in men than women, with a ratio of 3:1, and burden of disease is predominant in countries like China,
Mongolia, Southeast-Asia and Africa (Sub-Saharan, Western and Eastern), accounting for nearly 83%
of global liver cancer diagnosis [2]. Global liver cancer associated mortality rates follow the same
trends as incidence and prevalence of the disease [1,3]. Disability-Adjusted Life Year (DALY) is an
adequate measure to quantify burden of disease from morbidity and mortality. Liver cancer caused
~21 million DALYs in 2016, with Years of life lost (YLLs) accounting for 99% of DALYs [2]. Along
with lung cancers, liver cancers amount to the highest YLLs in the general population. The aggressive
nature and poor survival of liver cancer makes it an important public health issue worldwide [4].
Primary liver cancers include hepatocellular carcinomas (HCC), carcinomas of gallbladder,
intrahepatic cholangiocarcinomas (ICC) and extrahepatic cholangiocarcinomas. The vast majority
(85 to 90%) of primary liver cancers are HCC with ICC accounting for most of the other subtypes. The
burden of HCC is not evenly distributed worldwide and this disparity in HCC occurrence not only
depends on low sociodemographic indices of these regions but also on race and ethnicity. For example,
in the United States of America, a country with high sociodemographic index, incidence of HCC in
Asians was 2 fold higher than white Hispanics and 4 fold higher than Caucasians [5]. The reasons
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for this ethnic disparity might include differences in acquisition time of risk factors for chronic liver
disease leading to HCC.
2. Hepatocellular Carcinoma Risk Factors
About 80 to 90% of all HCC occurs within a background of chronic liver disease and cirrhosis.
Broadly, risk factors for cirrhosis in HCC patients can be dichotomised into viral and non-viral factors.
Major viral risk factors include hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and are
a global health problem resulting in chronic hepatitis that can progress to liver cirrhosis and HCC.
Large population-based studies in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) patients
have identified high serum HBV DNA, HCV RNA viral load respectively, as independent risk factors
for developing HCC [6,7].
HBV, a member of the Hepadnaviridae family, is a double-stranded DNA virus. Humans are the
only natural hosts of HBV and its tissue tropism is limited to liver and particularly to hepatocytes.
The virus is transmitted through contact with blood or other body fluids and vertically from infected
mother to the child. Once infected, manifestation of symptoms is age-dependent in acute stage. In
children, most infections are clinically silent. In adults, up to 30% of cases show transient jaundice and
flu-like symptoms and in up to 70% of cases an increase in serum transaminases are documented as
subclinical hepatitis [8]. Progression of CHB is often not apparent until cirrhosis or end-stage liver
disease is diagnosed. Current clinical practice guidelines suggest utilizing a combination of hepatitis B
e-antigen (HBeAg), hepatitis B surface antigen (HBsAg) and serum HBV DNA levels to assess risk of
HCC in CHB patients [9]. At present, there are no therapies to eliminate HBV infection. Management
of chronic disease is aimed at slowing the process of liver decompensation and to decrease systemic
viral load. Long-term administration of nucleos(t)ide analogues like entecavir, tenofovir disoproxil and
tenofovir alafenamide are treatment of choice, since they inhibit reverse transcription and restrict HBV
replication in majority of cases. Pegylated interferon-alfa might be considered in early stages of CHB
and is associated with severe side effects. Typically, treatment is initiated at HBV DNA > 2000 IU/mL
and elevated levels of liver transaminases [10].
HCV, a member of the Flaviviridae family, is an encapsulated positive-sense single-stranded
RNA virus. HCV spread is exclusively blood borne. In majority of cases, acute HCV infection
is asymptomatic and only 15% of cases present with jaundice, elevated transaminases. In adults,
55–85% cases develop CHC, with clinical course ranging from modest histopathological changes to
fulminant hepatitis that progresses to liver fibrosis, cirrhosis and HCC. However, the progression
of CHC to HCC occurs over several decades. Treatment regimens for HCV infection are aimed at a
curative outcome. Virological response means the virus is not detected upon treatment and efficacy of
treatment is measured in terms of sustained virological response (SVR). With direct-acting antiviral
(DAA) therapies becoming mainstay treatment options for HCV, outcome of HCV treatment has been
optimistic. Several DAA agents (sofosbuvir, simeprevir, velpatasvir, glecaprevir, asabuvir, ombitasvir)
have been approved and used alone or in combination with significant SVR rates of greater than 90%
after 8 to 12 weeks of treatment for almost all HCV genotypes [11]. It would be interesting to see long
term effects of DAA therapies on HCC risk as high rates of SVR and eradication of HCV will have
tremendous impact on chronic liver disease progression and HCC incidence.
Non-viral risk factors for HCC include cirrhosis from various causes (e.g., alcoholic cirrhosis);
obesity, diabetes mellitus type-2 (DM2); inherited errors of metabolism such as hereditary
hemochromatosis, porphyria cutanea tarda, and alpha-1 antitrypsin deficiency; Wilson’s disease [12].
Environmental exposure to aflatoxin, a natural product of Aspergillus fungus and excessive alcohol
intake are other risk factors for HCC [13]. Studies evaluating incidence risk of HCC in alcoholic
cirrhosis are confounded by the presence of other concomitant risk factors like CHB, CHC, obesity
and DM2 [14]. Furthermore, metabolic disorders (e.g., obesity, DM2, impaired glucose metabolism,
metabolic syndrome, non-alcoholic fatty liver disease (NAFLD)) are associated with increased risk of
HCC [15]. In the past decade numerous epidemiological studies have shown obesity and DM2 to be a
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risk factor for cancer [16,17]. In the USA, about 20% of all cancer deaths in men and 14% in women
were documented in individuals with body mass index (BMI) ≥ 30. The relative risk (RR) of dying due
to liver cancer in individuals with BMI ≥ 35 was highest among all cancers in men (RR = 4.52) [18].
Similar to obesity, epidemiological association studies have documented an increased risk for HCC in
DM2 patients [19,20].
3. Hepatocellular Carcinoma Prevention
HCC and cirrhosis are the major life-limiting consequences of progressive chronic fibrotic liver
disease, caused by any etiology. Although complete HCC tumor resection or ablation at early stages of
disease is effective, underlying tumor conducive tissue microenvironment in the remnant liver could
give rise to recurrence of tumors that progress to unresectable advanced-stage disease in majority of
patients. Once tumors progress to advanced-stage, current approved medical therapeutics provide
meagre survival benefit [21,22].
Thus, early detection and prevention of liver fibrosis progression to HCC would be an effective
strategy to ameliorate prognosis of patients. A bi-annual HCC screening for early detection of tumors,
as recommended by clinical practice guidelines, is an option [23]. Cancer prevention strategies can
also represent a valuable mean to decrease HCC burden in at-risk population.
Preventive interventions are aimed at eradicating risk factor affliction and interrupting cell
signaling pathways that promote carcinogenesis. Primary prevention focusses on prophylactic
elimination of HCC risk at an early stage before onset of any liver disease. These interventions could
include lifestyle modifications to combat obesity, intake of whole grains in diet is associated with
reduced risk of HCC [24], universal newborn immunization programs against HBV in the early nineties
and screening for HCV before blood transfusions during the same time-period have been effective in
preventing viral hepatitis infections. As a consequence of these public health measures, hepatitis virus
associated HCC risk has greatly decreased in general population [25,26]. Several decades of research
in large cohort studies have associated regular aspirin use with reduced HCC risk [27,28].
Secondary prevention encompasses chemointervention to prevent occurrence of HCC or
progression of pre-neoplastic hepatic foci to neoplasia in patients already exposed to aetiological
risks [29]. Owing to the long latency period between liver fibrosis and formation of tumors, HCC
secondary prevention makes for an attractive health measure. However, tumor heterogeneity and
incomplete understanding of mechanisms involved in neoplastic transformation in HCC predominantly
form the roadblocks to development of chemoprevention strategies [30]. Added to that, potential
chemoprevention agents would ideally have to be inexpensive and relatively tolerable in terms of
toxicity to be justified for long term use in clinical practice. Several epidemiological association studies
have indicated towards potential chemoprevention agents. Metformin use in DM2 population [31–33]
and statin use in cirrhotic patients [34] has been associated with lower incidence of HCC. An ongoing
phase 2 clinical trial is evaluating simvastatin as a chemoprevention agent in cirrhotic patients
(NCT02968810) but similar clinical trials with metformin (NCT02319200-Terminated, decision of
investigator, NCT02306070-withdrawn, insufficient funding) were not completed. Potential reduction
of HCC risk post management of chronic hepatitis B and C infection with nucleos(t)ide analogues and
DAA agents, respectively, had long been unclear. However, a European multi-center cohort study
reported that post entecavir/tenofovir therapy, risk of HCC occurrence beyond 5 years decreased in
younger patients without cirrhosis [35]. Interestingly, preservation of liver function in the long-term
improved over all survival in HCC patients after HCV eradication regimens with DAA agents [36].
Tertiary prevention includes chemointervention to prevent recurrence of HCC after initial resection
or liver transplantation. Clinical trials evaluating chemopreventive agents in a tertiary prevention
setting might be more appealing due to shorter timeframe of research studies in both academic and
pharmaceutical industry setting.
To overcome these challenges, pre-clinical animal models of HCC prevention empower researchers
to study complex and dynamic tumor pathophysiology systems. Particularly, in the area of precision
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cancer prevention, these animal models are invaluable since in-vitro systems cannot be configured to
reflect tissue or organ systems. Chronicity of tumorigenesis process in HCC further limits in-vitro
models. However, the animal models might not completely resemble the human disease process,
leading to false discovery of chemoprevention targets and biomarkers; these approaches may be
improved by more sophisticated modelling strategies (Figure 1) [37].
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4. Induction Models of Chronic Liver Injury and HCC
Several methods are utilized to induce chronic liver injury (CLI) in rodent models. These can
be broadly categorized into chemical and diet mediated induction of CLI. Assorted genotoxic and
hepatotoxic chemicals such as dimethylnitrosamine (DMN), diethylnitrosamine (DEN), thioacetamide
(TAA), carbon tetrachloride (CCl4), ethanol and aflatoxin are administered to induce HCC in drinking
water, by intraperitoneal injection, oral gavage or gaseous inhalation.
DEN is a genotoxic carcinogen that causes liver tumors in rodents in varied manner depending
on age, gender, dosage protocol and strains used. DEN mediated carcinogenesis animal models are
frequently used to investigate chemopreventive agents. In mice, chronic DEN additionally results in
various gastrointestinal tumors [38,39]. DEN is metabolised in the liver to electrophilic ethyldiazonium
ion and together with reactive oxygen species induces DNA damage [40]. This DNA damage in actively
proliferating hepatocytes initiates genome aberrations that eventually lead to tumorigenesis. Hence, a
single bolus intraperitoneal injection of DEN in 10 to 15-day old neonatal mice, causes liver tumors.
Several phytochemicals have been previously described as potential HCC chemopreventive agents
in DEN models [41]. These plant derivatives include curcumin, a low molecular weight polyphenol
derived from the root of Curcuma longa has been extensively studied to have hepatoprotective
properties. In both mouse and rat models, curcumin was shown to inhibit DEN-induced expression
of oncogenic HRAS, focal dysplasia and hepatocarcinogenesis [42–44]. Another phytochemical,
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resveratrol, abundant in peanuts and grapes, could interfere with DEN-induced hepatocarcinogenesis
by activating apoptotic pathways in male Wistar rats [45]. The most abundant of green tea polyphenols,
epigallocatechin gallate (EGCG) administration could decrease preneoplastic glutathione S-transferase
placental form (GST-P)-positive foci in rodent models [46].
Furthermore, several metabolic and signaling pathway regulators have been studied as
chemoprevention strategies in DEN rodent models. The following are prominent illustrations.
Inhibition of de novo lipid biosynthesis by targeting sterol regulatory element-binding protein (SREBP)
pathway prevents tumorigenesis in DEN mouse model [47]. Metformin, a dimethylbiguanide that
is frequently used as an anti-diabetic agent, could prevent hepatocarcinogenesis by suppressing
hepatic progenitor cell activation and advanced glycation end products in chronic DEN-induction
rat models [48,49]. Meta-analysis of genome-wide transcriptome profile from more than
500 human cirrhosis patients, identified co-regulated gene modules that could drive HCC risk
with lysophosphatidic acid (LPA) pathway as key target for chemoprevention. Autotaxin (ATX) and
Lysophosphatidic acid receptor 1 (LPAR1) are key upstream members of LPA pathway. Targeting ATX
and LPAR1 with respective inhibitors (AM063 and AM095) in chronic DEN-induced rat HCC model,
could attenuate liver fibrosis and prevent HCC via suppression of RhoA and ERK pathways [50].
DEN-induced initiation of carcinogenesis combined with choline-devoid methionine-deficient (CMD)
in F344 rats resembled human NAFLD with fatty liver changes and GST-P positive preneoplastic
hepatocyte foci driven by activation of transcription factor Nrf2. Genetic ablation of Nrf2 in this
nutritional rat model of liver carcinogenesis, prevented hepatocarcinogenesis initiation despite presence
of CMD-induced cirrhotic changes, thereby underlying the rationale for developing Nrf2 inhibitors
as chemoprevention agents [51]. Exhaustive description regarding DEN pathogenic mechanism and
protocols are described in detail elsewhere [52].
Liver fibrosis can be induced in rodents by surgical intervention (bile duct ligation) or more
commonly, by administration of hepatotoxins. CCl4 is a hepatotoxin that induces liver injury and
leads to panlobular parenchymal liver fibrosis [53]. CCl4 challenged mice are ideal tools for studying
hepatic remodeling [54]. In the liver, cytochrome P450 2E1 (CYP2E1) is a key metabolizing enzyme in
mediating the hepatic damage following CCl4 exposure [55]. Hence, CCL4 model is often utilized to
study anti-fibrosis treatment strategies. Epidermal growth factor (EGF) and its receptor expression are
upregulated in cirrhotic liver disease [56]. Therefore, EGFR inhibitors are an attractive chemopreventive
agents. Erlotinib, an EGFR inhibitor, could inhibit progression of liver fibrosis in DEN, BDL rat and
CCl4 mouse models. These antifibrotic effects resulted in abrogation of HCC development in DEN
rats [57]. However, in advanced HCC setting, addition of erlotinib to first-line sorafenib treatment did
not improve overall survival in a phase III clinical trial (NCT0901901) [58]. A pilot phase I/II clinical
trial with erlotinib for prevention of HCC in cirrhosis patients is ongoing (NCT02273362).
Non-alcoholic steatohepatitis (NASH) is emerging as a major risk factor for HCC development
owing to diet and lifestyle choices of modern life [59]. NASH is characterized by chronic hepatitis,
lobular inflammation and associated metabolic disease. To study chemoprevention strategies in
progression of NASH to HCC, STAM mouse model has been proposed [60]. In this mouse model,
metabolic disease is induced by low-dose streptozotocin in neonatal C57BL/6J and providing high-fat
diet (HFD) at 4 wks of age. As a consequence, STAM model mice develop NASH at 8 wks, HCC at
16–20 wks and effectively recapitulates NASH to HCC progression in human patients. Utilizing STAM
model, sodium-glucose co-transporter 2 (SGLPT2) inhibitor, canagliflozin, was shown to attenuate
steatohepatitis, liver fibrosis and tumorigenesis [61].
5. Genetically Engineered Animal Models of HCC Prevention
With the advent of genome-editing technologies, genetically engineered animal models of HCC
have been developed. However genetically engineered rats lag behind the mouse models. Most of
these genetically engineered mouse models (GEMs) are engineered using concepts derived from reverse
genetics, where in, frequent gene mutations or aberrant expression in HCC patients are introduced
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with the intent of generating spontaneous HCC development phenotypes [62]. Class II germinal
center kinases MST1/2 have been shown to act as tumor suppressors and knockout mice of these genes
developed spontaneous HCC, underlying the importance of Hippo-Lats-Yorkie signaling in regulating
tumorigenesis [63]. The PTEN lipid phosphatase, acts as a tumor suppressor gene by regulating
PI3-kinase signaling pathway. PTEN-null mice developed steatohepatitis and histological human
NASH features at 10 months, and progression to HCC took about 18 months [64]. In this mouse
model, novel STAT3 inhibitor C188-9 improved NASH and liver function along with reduced tumor
development. These hepatoprotective effects of C188-9 were attributed to downregulation of TREM-1
and interferon-γ inducible genes [65]. Additionally, maintaining PTEN-null mice on HFD for 40 weeks
resulted in exacerbation of inflammation, hepatic ballooning, liver fibrosis and increased NAFLD
activity score. These detrimental effects promoted by HFD was attributed to hypercholesterolemia
and VEGF mediated augmented angiogenesis. Addition of ezetimibe, a cholesterol lowering agent,
to HFD provided a hepatoprotective effect by attenuated steatohepatitis and suppressed tumor
formation via inhibition of angiogenesis. However, ezetimibe had no effect on tumorigenesis in
PTEN-null mice fed on normal diet [66]. Several studies have highlighted that activation of toll-like
receptor 4 (TLR4) in tumors and stromal cells effects tumor progression and evasion from immune
surveillance [67,68]. In accordance with these observations, TLR4 inhibitor, resatorvid, was shown to
prevent liver tumorigenesis in mice with hepatic deletion of PTEN [69].
Deficiencies in autophagy, a physiological process by which cells degrade cytoplasmic components
within lysosomes, are associated with increased tumorigenesis [70]. ATG5 and ATG7 are essential for
autophagic process and knockout mice of these genes developed liver tumors spontaneously [71]. More
than three decades ago similar observations of liver tumorigenesis were observed by overexpressing
c-MYC and TGFα in mice [72,73].
Hepatic stellate cells (HSCs) activation is a major contributor to liver fibrosis. Homodimer
PDGF-CC stimulates DNA replication in HSCs [74]. To assess the potential role of PDGF-C in driving
liver fibrosis, Pdgf-c expressing transgenic (Pdgf-c Tg) mice were generated [75]. These mice develop
liver fibrosis and steatosis by 9 months of age, followed by HCC at 12 months (~ in 80% of the mice).
Liver fibrosis in Pdgf-c Tg mice is perpetuated by activated HSCs resulting in transformation of
these cells to myofibroblast-like cells and promotes EMT transition [76]. Peretinoin, a member of the
acyclic retinoid family with vitamin-A like structure when administered at 0.06% in diet for 44 weeks,
could prevent liver fibrosis and tumors in Pdgf-c Tg mice by inhibiting angiogenesis and canonical
Wnt/β-catenin signaling [77]. However, hypervitaminosis A-induced osteopenia was encountered
in 5% of the experimental mice. A multicenter randomized study reported that branched chain
amino acids (BCAA) improved liver function and decreased Child-Pugh score in advanced cirrhosis
patients [78]. To study hepatoprotective mechanism of BCAA, Pdgf-c Tg mice were fed basal diet
supplemented with 3% BCAA for 20 weeks. BCAA intervention decreased incidence of fibrosis and
tumors in the liver but did not have any significant effect on liver function. These hepatoprotective
effect of BCAA was attributed to mTORC1-mediated inhibition of pro-fibrotic TGF-β1 signaling [79].
6. MircoRNAs and HCC Prevention Models
MicroRNAs (miRNAs) are a class of small non-coding RNAs of 19–24 nt in length and play
significant gene-regulatory role by binding to target mRNAs of multiple protein-coding genes. Hence
anti-miRs and miRNA mimics make for potential therapeutic agents. MiRNA dysregulation is a
key factor that has long been studied in formation of tumors [80]. Understanding of the important
differentially expressed miRNAs has been harnessed to model transgenic mice that spontaneously
develop liver tumors.
MiR-214 has been reported to be upregulated during progression of hepatic fibrosis and in chronic
hepatitis B and C patients [81]. Pdgf-c Tg mice treated at 9 weeks of age (liver fibrosis) and 32 weeks
(HCC) with locked nucleic acid anti-miR-214 showed a marked reduction in fibrosis and tumor
incidence and these effects were attributed to repression of EGFR and TGF-β signaling pathways [82].
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miR-122 is an abundant liver-specific miRNA that regulates hepatic homeostasis and functions as a
tumor suppressor [83]. In human NASH patients, miR-122 expression is downregulated in the liver [84].
Additionally, decreased expression of miR-122 corresponds with metastasis and poor outcome in HCC
patients [85]. Germline deletion of miR-122 locus in mice (miR122-KO) resulted in hepatic inflammation
that progressed to fibrosis, chronic steatohepatitis with age and eventually by 10–15 months of age,
these mice developed HCC [86]. In these mice, hepatic inflammation was attributed to chemokine
Ccl2, that is overexpressed in HCC [87], and subsequent infiltration of CD11bhiGr1+ inflammatory
cells. Replenishing miR-122 via adeno associated virus delivery, suppresses liver tumorigenesis in
non-inflammatory tet-o-MYC;LAP-tTA HCC mouse model [86,88].
Mir-21 and mir-148a are frequently dysregulated in HCC and are associated with poor prognosis [80,89].
Translating these observations in clinical specimens, anti-miR-21and mir-148a-minetics were shown to
abrogate liver fibrosis and progression to HCC in hepatic PTEN null mice. HCC preventive effects of
targeting miR-21 were attributed to depletion of CD24+ liver progenitor cells, S100A4+ tumor associated
stromal cells and NOTCH pathway [90]. While miR-148a-mimetics induced hepatocyte differentiation
and suppressed NOTCH activity resulting in prevention of tumor development. Furthermore,
targeting NOTCH with an inhibitor OR4929097 resulted in similar hepatoprotective effects as seen with
miR-148a-mimetics, hence highlighting NOTCH as a promising target for HCC chemoprevention [91].
MiR-221 is one of the most frequently up-regulated miRNAs in HCC patients and is regarded as an
oncogenic miRNA [80,92]. Taking these observations into account, we developed liver-specific miR-221
overexpressing transgenic mouse model (TG221) that exhibited strong predisposition to development
of spontaneous liver tumors at 9–12 months of age. In this model, liver tumors are accompanied by
hepatomegaly, steatohepatitic changes, hepatocyte degeneration marked by enlarged dysplastic nuclei
and focal coagulative necrosis. At the molecular level, significant inhibition of Cdkn1b/c, miR-122 and
miR-199 was observed [93]. Autochthonous tumorigenesis in these mice could be accelerated by low
dose DEN i.p in 10–15-day old mice and by chronic CCl4 challenge for 14 weeks in adult mice. The
latter providing an added advantage of liver tumors that developed in cirrhotic liver background.
Aiming to test the HCC prophylactic potential of miRNA-based molecules, we demonstrated that
miR-221 inhibition and miR-199 replacement were also able to prevent malignant transformation of
nodular lesions in CCl4-treated TG221 mice, without inducing toxicity [94]. In both settings, biological
outcomes were accompanied by molecular regulation of miR-221 and miR-199 target proteins. Hence,
confirming the pivotal importance of these miRNAs in regulation of cancer-related pathways.
Additionally, progression of fibrosis could be studied in TG221-CCl4 mouse model. Early or first
signs of portal liver fibrosis was observed after 3 weeks of initiation CCl4 challenge and gradually
progressed to cirrhosis by 14 weeks. TG221-CCl4 made for a utilitarian model, whereby early
chemointervention strategies could be studied. To this end we studied chemopreventive effect of early
metformin intervention. TG221-CCl4 at 3 weeks were treated with daily metformin treatment, that was
continued until the experimental endpoint (10 weeks after cessation of CCl4 challenge). Metformin
could effectively attenuate progression of liver fibrosis and as a consequence prevent formation of
liver tumors. This hepatoprotective effect of metformin was largely mediated by suppressing hepatic
stellate cell activation, PI3K/AKT and EMT pathways in the liver [95].
7. Conclusions
Undeniably, most cases of HCC develop in the setting of chronic liver disease, characterized by
cirrhosis, liver fibrosis and steatosis. GEMs described above cater to genetic perturbation in oncogenes
and tumor suppressor genes. Although these models are invaluable in studying molecular and
signaling pathway interactions during tumor initiation and progression, their utility is limited by
long incubation times and inability to recapitulate underlying liver disease hierarchy. Several toxins,
carcinogens and modified diets are combined with GEMs to accelerate tumorigenesis and closely
resemble underlying human liver disease. Evidently, no one rodent model could recapitulate the
process of human hepatocarcinogenesis in its entirety. Suppression of PTEN expression and activity
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appears to be a paramount molecular event in HCC of various aetiologies [96,97]. Hence, reverse
engineering to reflect liver specific PTEN downregulation as seen in PTEN-null and TG221 (PTEN
being a major miR-221 target) mouse models combined with chronic liver injury induction could be
useful models to test precision chemoprevention agents. Notably, repeated low dose DEN induction
in rats was shown to concur with HCC-risk gene expression signature [98]. There are adequate
pre-clinical evidences regarding chemopreventive agents that have shown promise and could be
translated to clinical application (Table 1). However, considering long latency period involved in
progression of liver fibrosis or cirrhosis to HCC, prevention directed clinical trials would be spread
over a longer duration and cohort sample size might need to be large to determine smaller effect size.
To overcome these challenges, potential chemoprevention agents have been suggested to be introduced
into tertiary prevention wherein prevention of recurrence could be tested [99]. Finally, non-invasive
biomarkers of progression of HCC from early stages of fibrosis to cirrhosis and eventual frank HCC,
could define appropriate clinical endpoint to assess HCC prevention drugs [100]. Advancement of
clinical availability of chemopreventive agents could significantly improve the prognosis of chronic
liver disease patients and decrease HCC incidence and mortality.
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Table 1. HCC prevention rodent models and intervention strategies.
Animal Model
Induction Chronic Liver Injury Pathogenesis Preventive Intervention Ref.
Rodent Strain
RAT
(Wistar) DEN Repeated weekly IP Fibrosis (8 wks) progress to cirrhosis (12 wks) andHCC (18 wks)
Metformin, AM063, AM095,
erlotinib, gefitinib [48,50,57,101]
(F344) DEN CMD diet Steatosis progresses to steatohepatitis and fibrosiswith GST-P +ve pre-neoplastic after 17 wks NRF2 KO [51]
(Wistar) BDL Fibrosis after 3 wks Erlotinib [57]
MOUSE
(C57BL/6J) DEN Lipid biosynthesis (SREBP pathway) regulatesHCC initiation and development Gp78 KO/SCAP KO/Betulin [47]
(A/J) CCL4
Repeated thrice weekly
PO Fibrosis after 18 wks Erlotinib [57]
(C57BL/6J) STZ+HFD Neonatal low-dose STZSQ & HFD at 4 wks NASH by 8 wks progress to HCC by 16-20 wks Canagliflozin [60,61]
AlbCrePtenflox/flox
NASH- hepatomegaly, steatosis, inflammation,
fibrosis and progress to HCC C 188-9 [64,65]
AlbCrePtenflox/flox HFD for 40 wks
NASH-related cirrhosis and HCC with
hypercholesterolemia Ezetimibe [66]
PtenloxP/loxP; Alb-Cre+ HCC by 8–9 months
Resatorvid, anti-miR-21,
miR-148a, [69,90,91,102]





cycles for 14 weeks.
Phenobarbital in drinking
water.





miR-221 transgenic CCL4 PO repeated thriceweekly for 14 weeks Early fibrosis progress to cirrhosis and HCC Metformin [95]
Tet-o-MYC; LAP-tTA MYC overexpression leads to liver tumors by 15wks. No fibrosis/cirrhosis miR-122 [86,88]
C57BL/KsJ-+Lepr db
/+Lepr db
DEN in drinking water
for 2 wks
DEN initiates tumorigenesis that is promoted by
obesity and diabetes. Chronic inflammation and
steatosis progress to HCC
Tofogliflozin [103]
DEN, diethylnitrosamine; CMD, choline-devoid methionine-deficient; CCL4, carbon tetrachloride; BDL, Bile duct ligation; HCC, Hepatocellular carcinoma; NASH, non-alcoholic
steatohepatitis; GST-P, glutathione S-transferase placental form; SREBP, sterol regulatory element-binding protein.; SCAP, SREBP cleavage-activating protein; HFD, high fat diet; BCAA,
branched chain amino acids; LNA, locked nucleic acid; PDGF-C, Platelet-derived growth factor C; IP, intraperitoneal injection; PO, oral gavage; STZ, streptozotocin; SQ, subcutaneous.
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